Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

The introduction of tacrolimus in clinical practice has improved patient survival after organ transplant. However, despite the long use of tacrolimus in clinical practice, the best way to use this agent is still a matter of intense debate. The start of the genomic era has generated new research areas, such as pharmacogenetics, which studies the variability of drug response in relation to the genetic factors involved in the processes responsible for the pharmacokinetics and/or the action mechanism of a drug in the body. This variability seems to be correlated with the presence of genetic polymorphisms. Genotyping is an attractive option especially for the initiation of the dosing of tacrolimus; also, unlike phenotypic tests, the genotype is a stable characteristic that needs to be determined only once for any given gene. However, prospective clinical studies must show that genotype determination before transplantation allows for better use of a given drug and improves the safety and clinical efficacy of that medication. At present, research has been able to reliably show that the CYP3A5 genotype, but not the CYP3A4 or ABCB1 ones, can modify the pharmacokinetics of tacrolimus. However, it has not been possible to incontrovertibly show that the corresponding changes in the pharmacokinetic profile are linked with different patient outcomes regarding tacrolimus efficacy and toxicity. For these reasons, pharmacogenetics and individualized medicine remain a fascinating area for further study and may ultimately become the face of future medical practice and drug dosing.

• Publication year

  2013

• Venue

  World Journal of Gastroenterology

• Publication date

  2013-12-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3748/wjg.v19.i48.9156PMID 24409044PMCID PMC3882390
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.

  2013cited by this paper
• CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes.

  2013cited by this paper
• Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism – a prospective, randomized, controlled study

  2013cited by this paper
• CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.

  2013cited by this paper
• Genes and beans: pharmacogenomics of renal transplant.

  2013cited by this paper
• From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation.

  2013cited by this paper
• Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.

  2013cited by this paper
• CYP3A5 Genotype, but Not CYP3A4*1b, CYP3A4*22, or Hematocrit, Predicts Tacrolimus Dose Requirements in Brazilian Renal Transplant Patients

  2013cited by this paper
• Effect of the P450 oxidoreductase *28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers

  2013cited by this paper
• Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation.

  2013cited by this paper
• CYP2C8*3 Polymorphism and Donor Age are Associated With Allograft Dysfunction in Kidney Transplant Recipients Treated With Calcineurin Inhibitors

  2013cited by this paper
• CYP3A5 Genotype Had no Impact on Intrapatient Variability of Tacrolimus Clearance in Renal Transplant Recipients

  2013cited by this paper
• Angiotensinogen Polymorphisms and Post-Transplantation Diabetes Mellitus in Korean Renal Transplant Subjects

  2013cited by this paper
• Unusual high dose of tacrolimus in liver transplant patient, a case report

  2012cited by this paper
• Genetic Polymorphisms of the Transcription Factor NFATc4 and Development of New-Onset Diabetes After Transplantation in Hispanic Kidney Transplant Recipients

  2012cited by this paper
• Cytochrome P450 variations in different ethnic populations

  2012cited by this paper
• Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients.

  2012cited by this paper
• Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.

  2012cited by this paper
• Measurement and Compartmental Modeling of the Effect of CYP3A5 Gene Variation on Systemic and Intrarenal Tacrolimus Disposition

  2012cited by this paper
• Genetic and Clinical Determinants of Early, Acute Calcineurin Inhibitor-Related Nephrotoxicity: Results From a Kidney Transplant Consortium

  2012cited by this paper
• Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation

  2012cited by this paper
• Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.

  2012cited by this paper
• CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.

  2011cited by this paper
• Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.

  2011cited by this paper
• Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

  2011cited by this paper
• A Review on Therapeutic Drug Monitoring of Immunosuppressant Drugs

  2011cited by this paper
• A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

  2011cited by this paper
• The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.

  2011cited by this paper
• Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis

  2011cited by this paper
• Do Drug Transporter (ABCB1) SNPs Influence Cyclosporine and Tacrolimus Dose Requirements and Renal Allograft Outcome in the Posttransplantation Period?

  2011cited by this paper
• Present and future of immunosuppressive therapy in kidney transplantation.

  2011cited by this paper
• Genetic polymorphisms and individualized tacrolimus dosing.

  2010cited by this paper
• Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor‐related neurotoxicity after hematopoietic stem cell transplantation

  2010cited by this paper
• Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II

  2010cited by this paper
• Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I

  2010cited by this paper
• Intronic polymorphisms of cytochromes P450

  2010cited by this paper
• Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing

  2010cited by this paper
• Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation.

  2010cited by this paper
• A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients.

  2010cited by this paper
• Genetic polymorphisms and individualized tacrolimus dosing.

  2010cited by this paper
• How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments.

  2010cited by this paper
• Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients

  2010cited by this paper
• THE USE OF SINGLE NUCLEOTIDE POLYMORPHISM (SNP) AND MULTIPLE LOCUS VARIABLE NUMBER TANDEM REPEAT (MLVA) ANALYSES TO STUDY THE POPULATION GENETICS OF PATHOGENIC MICROBES

  2009cited by this paper
• The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.

  2009cited by this paper
• Tacrolimus Concentrations in Relation to CYP3A and ABCB1 Polymorphisms Among Solid Organ Transplant Recipients in Korea

  2009cited by this paper
• Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations

  2008cited by this paper
• Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation

  2008cited by this paper
• CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients

  2008cited by this paper
• Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease

  2008cited by this paper
• Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.

  2008cited by this paper
• Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients

  2008cited by this paper
• Pharmacokinetic principles of immunosuppressive drugs.

  2008cited by this paper
• A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity

  2007cited by this paper
• Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus.

  2007cited by this paper
• CYP3A5*3 and CYP3A4*1B Allele Distribution and Genotype Combinations: Differences Between Spaniards and Central Americans

  2007cited by this paper
• Therapeutic monitoring of calcineurin inhibitors for the nephrologist.

  2007cited by this paper
• Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate‐binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms

  2007cited by this paper
• Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity.

  2007cited by this paper
• CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal Recipients

  2007cited by this paper
• 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation

  2007cited by this paper
• Significance of the Minor Cytochrome P450 3A Isoforms

  2006cited by this paper
• Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements.

  2006cited by this paper
• Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients

  2006cited by this paper
• Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients

  2006cited by this paper
• The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients.

  2006cited by this paper
• Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients

  2006cited by this paper
• Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.

  2005cited by this paper
• Differences in CYP3A5*3 Genotype Distribution and Combinations With Other Polymorphisms Between Spaniards and Other Caucasian Populations

  2005cited by this paper
• Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians

  2005cited by this paper
• Effect of Common CYP 3 A 4 and CYP 3 A 5 Variants on the Pharmacokinetics of the Cytochrome P 450 3 A Phenotyping ProbeMidazolam in Cancer Patients

  2005cited by this paper
• Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability

  2005cited by this paper
• CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele

  2005cited by this paper
• Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

  2005cited by this paper
• Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR‐1, CYP3A4, and CYP3A5 genes

  2004cited by this paper
• Pharmacokinetics of immunosuppressants: a perspective on ethnic differences.

  2004cited by this paper
• CYP3A5 and MDR1 Genetic Polymorphisms and Cyclosporine Pharmacokinetics After Renal Transplantation

  2004cited by this paper
• CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.

  2004cited by this paper
• Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients

  2004cited by this paper
• From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy

  2004cited by this paper
• Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.

  2003cited by this paper
• [Calcineurin inhibitors and mechanisms that are responsible for the appearance of post-transplant diabetes mellitus].

  2003cited by this paper
• Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.

  2003cited by this paper
• Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

  2003cited by this paper
• Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T lymphocytes.

  2003cited by this paper
• Increased transcriptional activity of the CYP3A4*1B promoter variant

  2003cited by this paper
• Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene

  2002cited by this paper
• CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity

  2002cited by this paper
• Genetic contribution to variable human CYP3A-mediated metabolism.

  2002cited by this paper
• G enetic contribution to variable human CYP 3 A-mediated metabolism

  2002cited by this paper
• The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.

  2002cited by this paper
• Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

  2002cited by this paper
• Insights into pharmacogenomics and its impact upon immunosuppressive therapy.

  2002cited by this paper
• Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine*

  2002cited by this paper
• Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations.

  2002cited by this paper
• Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.

  2002cited by this paper
• MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity.

  2001cited by this paper
• The Gut as a Barrier to Drug Absorption

  2001cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper
• No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients.

  2001cited by this paper
• The genetic determinants of the CYP3A5 polymorphism.

  2001cited by this paper

• Tacrolimus-induced reversible posterior leukoencephalopathy syndrome in a child with nephrotic syndrome: a case report

  2026cites this paper
• Belatacept in Solid Organ Transplantation: Current Kidney Applications, Future Perspectives in Other Organs, and Clinical Implications.

  2026cites this paper
• Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review.

  2025cites this paper
• TACROLIMUS VARIABILITY FACTORS AND INTERPLAY WITH KIDNEY GRAFT FUNCTION

  2025cites this paper
• Integration of urine retinol-binding protein and genetic markers for early prediction of tacrolimus nephrotoxicity using machine learning

  2025cites this paper
• Tacrolimus-Induced Neurotoxicity After Transplant: A Literature Review

  2024cites this paper
• Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy

  2024cites this paper
• Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study

  2024cites this paper
• Tacrolimus Concentration/Dose Ratio: A Tool for Guiding Tacrolimus Dosage Post-renal Transplantation

  2024cites this paper
• The Mineralocorticoid Receptor on Smooth Muscle Cells Promotes Tacrolimus-Induced Renal Injury in Mice

  2023cites this paper
• CYP3A5 Polymorphisms Leading to Tacrolimus Toxicity Following an Adult Renal Transplant

  2023cites this paper
• The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living‐donor Egyptian kidney transplanted patients

  2023cites this paper
• Effectiveness and safety of once‐daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study

  2023cites this paper
• The Role of Sensory Innervation in Homeostatic and Injury-Induced Corneal Epithelial Renewal

  2023cites this paper
• Quantitative methods for optimizing patient outcomes in liver transplantation.

  2023cites this paper
• Tacrolimus-induced akinetic mutism and persistent dysarthria following orthotopic liver transplantation

  2023cites this paper
• Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted Patients

  2022cites this paper
• Risks and ways of preventing kidney dysfunction in drug-induced immunosuppression in solid organ recipients

  2022cites this paper
• Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis.

  2022cites this paper
• Sustained Release of Tacrolimus From a Topical Drug Delivery System Promotes Corneal Reinnervation

  2022cites this paper
• Effect of CYP3A4 and PPARA polymorphism on concentration-to-dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients

  2022cites this paper
• Impact of CYP3A7, CYP2D6 and ABCC2/ABCC3 polymorphisms on tacrolimus steady state concentrations in Bulgarian kidney transplant recipients

  2022cites this paper
• Evaluation of Pharmacogenetics of Drug-Metabolizing Enzymes and Drug Efflux Transporter in Renal Transplants Receiving Immunosuppressants

  2022cites this paper
• Tacrolimus-Induced Neurotoxicity in Early Post-Liver Transplant Saudi Patients: Incidence and Risk Factors

  2022cites this paper
• Rapid clearance of tacrolimus blood concentration triggered by variant pharmacogenes

  2022cites this paper
• Microbiome analysis, the immune response and transplantation in the era of next generation sequencing.

  2021cites this paper
• The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients

  2021cites this paper
• Acute Rejection in the Modern Lung Transplant Era

  2021cites this paper
• Influence of ABCB1 gene polymorphism on concentration to dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients

  2021cites this paper
• Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients

  2021cites this paper
• Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients

  2021cites this paper
• CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients

  2021cites this paper
• Effect of cytochrome P450 3A5 polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients

  2020cites this paper
• Importance of genetic polymorphisms in liver transplantation outcomes

  2020cites this paper
• Impact of body composition on pharmacokinetics of tacrolimus in liver transplantation recipients

  2020cites this paper
• Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients

  2020cites this paper
• Graft and patient survival after renal transplantation in the period from 1996-2017 in Military Medical Academy, Belgrade, Serbia

  2020cites this paper
• Impact of tacrolimus versus cyclosporine on one-year renal transplant outcomes: A single-centre retrospective cohort study

  2020cites this paper
• Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A‐status in liver transplant recipients

  2020cites this paper
• Evaluation of the impact of Tacrolimus-based immunosuppression on Heidelberg liver transplant cohort (HDTACRO)

  2020cites this paper
• National survey of physicians’ perspectives on pharmacogenetic testing in solid organ transplantation

  2020cites this paper
• The First Asian Kidney Transplantation Prediction Models for Long-term Patient and Allograft Survival

  2020cites this paper
• Tacrolimus: Influence of the Posttransplant Concentration/Dose Ratio on Kidney Graft Function in a Two-Year Follow-Up

  2019cites this paper
• CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients

  2019cites this paper
• Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients

  2019cites this paper
• Melding Pharmacogenomic Effect of MDR1 and CYP3A5 Gene Polymorphism on Tacrolimus Dosing in Renal Transplant Recipients in Northern India

  2019cites this paper
• Clinical observation on the effect of Wuzhi soft capsule on FK506 concentration in membranous nephropathy patients

  2019cites this paper
• Effectiveness and safety of the conversion to MeltDose® extended‐release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study

  2019cites this paper
• Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children

  2018cites this paper
• management of metastatic castrate resistant prostate cancer following renal transplantation

  2018cites this paper
• Acute Cellular Rejection: Is It Still Relevant?

  2018cites this paper
• Long-lasting immunosuppressive effects of tacrolimus-loaded micelle NK61060 in preclinical arthritis and colitis models.

  2018cites this paper
• Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation

  2018cites this paper
• Anellovirus loads are associated with outcomes in pediatric lung transplantation

  2018cites this paper
• An equation for tacrolimus daily dose calculation in renal transplant patients - simple and cost saving?

  2018cites this paper
• ASOCIACIÓN ENTRE LOS NIVELES DE TACROLIMUS Y LA FUNCIÓN RENAL TEMPRANA, RECHAZO AGUDO E INFECCIONES TEMPRANAS EN EL TRASPLANTE RENAL, EXPERIENCIA DE UN CENTRO

  2018cites this paper
• Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation

  2017cites this paper
• Study of the Influence of a Combination of Pharmacogenetic Variables on Tacrolimus Exposure: A Population Pharmacokinetic Approach

  2017cites this paper
• An Antigen-Presenting and Apoptosis-Inducing Polymer Microparticle Prolongs Alloskin Graft Survival by Selectively and Markedly Depleting Alloreactive CD8+ T Cells

  2017cites this paper
• The relationship between tacrolimus concentration-dose ratio and genetic polymorphism in patients subjected to renal transplantation

  2017cites this paper
• Clementine juice has the potential for drug interactions – In vitro comparison with grapefruit and mandarin juice

  2017cites this paper
• Association of CYP3A5 and POR polymorphisms with the maintenance tacrolimus dosage requirement in Thai recipients of kidney transplants

  2017cites this paper
• Pharmacokinetics of prolonged‐release tacrolimus versus immediate‐release tacrolimus in de novo liver transplantation: A randomized phase III substudy

  2017cites this paper
• A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach

  2017cites this paper
• Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients

  2017cites this paper
• Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know

  2017cites this paper
• Efficacy of hydrodynamic interleukin 10 gene transfer in human liver segments with interest in transplantation

  2017cites this paper
• Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group

  2017cites this paper
• Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients

  2017cites this paper
• Effect of ABCB1 (3435C>T) and CYP3A5 (6986A>G) genes polymorphism on tacrolimus concentrations and dosage requirements in liver transplant patients

  2017cites this paper
• University of Birmingham Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients

  2017cites this paper
• Relationships of Selected CYP and ABCB1 Single Nucleotide Polymorphisms and Patient Characteristics with the Pharmacokinetics of Twice Daily Tacrolimus and Advagraf® in Renal Transplant Recipients

  2016cites this paper
• The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation.

  2016cites this paper
• Clinical implementation of pharmacogenetics

  2016cites this paper
• Pemphigus vulgaris and blood group antigens: no relationship

  2016cites this paper
• Oral tacrolimus: a treatment option for recalcitrant erosive lichen planus

  2016cites this paper
• Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation.

  2016cites this paper
• High on Cannabis and Calcineurin Inhibitors: A Word of Warning in an Era of Legalized Marijuana

  2016cites this paper
• TAC-TIC use of tacrolimus-based regimens in lupus nephritis

  2016cites this paper
• Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of Literature

  2016cites this paper
• Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients

  2016cites this paper
• Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation

  2015cites this paper
• Current State of Immunosuppression: Past, Present, and Future.

  2015cites this paper
• Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients

  2015cites this paper
• Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation

  2015cites this paper
• Etude rétrospective de l'influence des polymorphismes génétiques de CYP3A4, CYP3A5 et ABCB1 des donneurs et des receveurs sur les effets des immunosuppresseurs en transplantation hépatique

  2015cites this paper
• Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy: the influence of gender and comedication.

  2015cites this paper
• Tacrolimus Prolonged Release (Envarsus®): A Review of Its Use in Kidney and Liver Transplant Recipients

  2015cites this paper
• Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro

  2015cites this paper
• Rash and multiorgan dysfunction following lamotrigine: could genetic be involved?

  2015cites this paper
• Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2‐year prospective study

  2015cites this paper
• Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.

  2015cites this paper
• Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations

  2014cites this paper